95331-56-9

Usage

Uses

Used in Pharmaceutical Research:
4-OXAZOLO[4,5-B]PYRIDIN-2-YL-PHENYLAMINE is used as a pharmaceutical agent for its potential therapeutic applications. Its unique structure and properties make it a candidate for further exploration in the development of new drugs and treatments.
Used in Organic Synthesis:
In the field of organic synthesis, 4-OXAZOLO[4,5-B]PYRIDIN-2-YL-PHENYLAMINE is used as a precursor for the synthesis of other biologically active compounds. Its complex molecular structure allows for the creation of a variety of new chemical entities with potential applications in various industries.
Further studies are necessary to fully understand the properties and potential uses of 4-OXAZOLO[4,5-B]PYRIDIN-2-YL-PHENYLAMINE, ensuring that its applications are maximized and its benefits realized in the appropriate contexts.

Upstream product

• 273-97-2 oxazolo<4,5-b>pyridine 
• 540-37-4 p-aminoiodobenzene 
• 16867-03-1 2-amino-3-hydroxypyridine 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 428443-57-6 3-chloro-4-methoxy-N-((4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)carbamothioyl)benzamide 
• 347322-23-0 2-(4-methoxyphenoxy)-N-(4-(oxazolo[4,5-b]pyridin-2-yl)phenyl)acetamide 
• 433703-38-9 N-(4-oxazolo[4,5-b]pyridin-2-ylphenyl)-3-pyridinecarboxamide 
• 314044-24-1 C₂₁H₁₇N₃O₄ 
• 925431-61-4 C₂₁H₁₈N₄O₂ 
• 180972-88-7 4-(4-oxazolo[4,5-b]pyridin-2-yl-phenylazo)-phenylamine 
• 180972-87-6 4-(4-oxazolo[4,5-b]pyridin-2-yl-phenylazo)-phenol 

Relevant academic research and scientific papers

Small molecule inhibition of microRNA-21 expression reduces cell viability and microtumor formation

MicroRNAs (miRNAs) are short, non-coding RNA molecules estimated to regulate expression of a large number of protein-coding genes and are implicated in a variety of biological processes such as development, differentiation, proliferation, and cell surviva

N-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors

Fatty acid amide hydrolase (FAAH) is a promising target for the development of drugs to treat neurological diseases. In search of new FAAH inhibitors, we identified 2-(4-cyclohexylphenoxy)-N-(3-(oxazolo[4,5-b]pyridin-2-yl)phenyl)acetamide, 4g, with an IC50 of 2.6 μM as a chemical starting point for the development of potent FAAH inhibitors. Preliminary hit-to-lead optimisation resulted in 2-(4-phenylphenoxy)-N-(3-(oxazolo[4,5-b]pyridin-2-yl)phenyl)acetamide, 4i, with an IC50 of 0.35 μM.

Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators

SIRT1 is an NAD+-dependent protein deacetylase that appears to produce beneficial effects on metabolic parameters such as glucose and insulin homeostasis. Activation of SIRT1 by resveratrol (1) has been shown to modulate insulin resistance, increase mitochondrial content and prolong survival in lower organisms and in mice on a high fat diet. Herein, we describe the identification and SAR of a series of oxazolo[4,5-b]pyridines as novel small molecule activators of SIRT1 which are structurally unrelated to and more potent than resveratrol.

Unprecedentedly mild direct Pd-catalyzed arylation of oxazolo[4,5-b] pyridine

Pd-catalyzed C-2 arylation of oxazolo[4,5-b]pyridine proceeds efficiently at 30°C and tolerates a variety of aryl halides, including derivatized amino acids for which no racemization was observed during the reaction. Experimental evidence for facile depro

Biological evaluation of hepatitis C virus helicase inhibitors

A small chemical library has been synthesized and assayed for inhibition of HCV helicase activity. This study provides the structure-activity relationship of the reported inhibitors, with emphasis placed on the aminophenylbenzimidazole moiety and the link